CDK4/6 Inhibitors Enhance Treatment for HR+ Metastatic Breast Cancer
The use of CDK4/6 inhibitors remains pivotal in the treatment of hormone receptor (HR)–positive metastatic breast cancer, according to Dr. Neelam V. Desai, a medical oncologist at the Atrium Health…